A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Clinical trial NCT00354146 · COMPLETED

Trial details

NCT number: NCT00354146
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia, Nonlymphocytic, Acute

Start date: 2001-04-01
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.